EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Selenium and selenoproteins: key regulators of ferroptosis and therapeutic targets in cancer

Jaewang Lee, Jong-Lyel Roh

Journal of Molecular Medicine · 2025-08 · 103 (8) · 899-911

DOI: 10.1007/s00109-025-02563-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Molecular Medicine, online erschienen am 17.06.2025. Verfasst von Jaewang Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Gyeonggi-Do, 13496, Republic of Korea. Hauptthemen laut MEDLINE: Ferroptosis, Selenium, Neoplasms, Selenoproteins. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 114 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The interplay between selenium (Se) metabolism and ferroptosis presents a compelling area of study in cancer biology. This review synthesizes the current understanding of key pathways implicated in ferroptosis susceptibility, with a focus on the role of selenoproteins, particularly glutathione peroxidase 4 (GPX4), which mitigates lipid peroxidation and prevents ferroptotic cell death through the system Xc-/GSH axis. Additionally, selenoprotein P contributes to Se transport, playing a crucial role in ferroptosis resistance observed in certain cancers. Targeting Se pathways, especially disrupting GPX4 and selenoprotein P functions, offers promising avenues for cancer therapy. The differential dependence of cancer cells on Se and selenoproteins highlights the potential for selective induction of ferroptosis in malignant cells. Future research should focus on unraveling the mechanistic underpinnings of Se-mediated ferroptosis and exploring combinatorial therapeutic strategies. This review sets the stage for innovative approaches that leverage Se metabolism to enhance cancer treatment efficacy through ferroptosis modulation. KEY MESSAGES: Selenium (Se) and selenoproteins regulate ferroptosis, a lipid peroxidation-driven form of cell death. GPX4, a Se-dependent enzyme, defends cells by neutralizing lipid hydroperoxides. Xc-/GSH/GPX4 and FSP1-CoQ10 pathways are critical in modulating ferroptosis susceptibility. Selenoprotein P, SEPHS2, and SQOR highlight vulnerabilities in Se-dependent cancer cell survival. Se's role in balancing antioxidant defense and ferroptosis offers therapeutic insights.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisSeleniumNeoplasmsSelenoproteinsHumansAnimalsLipid PeroxidationPhospholipid Hydroperoxide Glutathione Peroxidase

Stichwörter der Autor:innen

BiosynthesisCancerFerroptosisSeleniumSelenoprotein

Substanzen

SeleniumSelenoproteinsPhospholipid Hydroperoxide Glutathione Peroxidase

Autor:innen und Institutionen

  • Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Gyeonggi-Do, 13496, Republic of Korea.
  • Logsynk, Seoul, Republic of Korea.
  • Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Gyeonggi-Do, 13496, Republic of Korea. rohjl@cha.ac.kr.
  • Department of Biomedical Science, General Graduate School, CHA University, Pocheon, Republic of Korea. rohjl@cha.ac.kr.

Zitieren

APA

Lee, J., & Roh, J. L. (2025). Selenium and selenoproteins: key regulators of ferroptosis and therapeutic targets in cancer. Journal of Molecular Medicine, 103(8), 899-911. https://doi.org/10.1007/s00109-025-02563-8

Vancouver

Lee J, Roh JL. Selenium and selenoproteins: key regulators of ferroptosis and therapeutic targets in cancer. Journal of Molecular Medicine. 2025;103(8):899-911. doi:10.1007/s00109-025-02563-8

BibTeX
@article{Lee2025,
  author = {Lee, Jaewang and Roh, Jong-Lyel},
  title = {Selenium and selenoproteins: key regulators of ferroptosis and therapeutic targets in cancer},
  journal = {Journal of Molecular Medicine},
  year = {2025},
  volume = {103},
  number = {8},
  pages = {899--911},
  doi = {10.1007/s00109-025-02563-8}
}
Kostenlos starten →